South Korea-based Daewoong Pharmaceutical said it has received the Indian regulatory approval to test its anti-parasitic drug 'niclosamide' to treat COVID-19 patients in early-stage human trials. The phase 1 trial, approved by the Central Drugs Standard Control Organisation, will involve about 30 healthy participants. It will be testing the drug in partnership with New Delhi-based Mankind Pharma.